Blog · Evidence, in plain language

A new ADHD medicine: what we tell patients who ask.

Patients have begun asking about Simtriyo, a medicine for ADHD approved this summer and given its controlled substance schedule this fall. The short version is reassuring and limited at the same time: the approval is genuine, the measured benefit over placebo is modest, and no study has compared it with the ADHD medicines already in wide use. This is the summary we give, with links to the fuller posts.

By Karel Winner, DNP, PMHNP-BC · Published November 10, 2026

This post is education from the practice, not medical advice. It summarizes two regulator decisions and the FDA label. It is not a recommendation about any individual's care, and it makes no promise that this practice will prescribe the product discussed.

The short answer

Centanafadine, brand name Simtriyo, is a stimulant medicine in a new class for ADHD: a norepinephrine-dopamine-serotonin reuptake inhibitor. The FDA approved it on July 24, 2026 for adults and for patients aged 6 years and older weighing at least 20 kg. On October 30, 2026, the DEA placed it in Schedule III of the Controlled Substances Act through an interim final rule, with comments due November 30, 2026. Its approval rests on four randomized, placebo-controlled, six-week trials enrolling 1,845 people in total, in which symptom scores improved more on the medicine than on placebo, by 2.7 to 5.6 points beyond placebo on the rating scales used. Our practice treats patients aged 17 and older, so the adult and older adolescent evidence is the part relevant to the people we see.

What we are careful about

Every approval trial compared this medicine with placebo. None compared it with methylphenidate, an amphetamine product, or any non-stimulant, so no one can honestly rank it against the medicines a patient may already take. The trials ran six weeks, which leaves long-term benefit and safety unmeasured, and the two adult trials studied a different formulation of the same medicine. The FDA label carries a boxed warning covering higher rates of suicidal thoughts and behaviors in treated children aged 6 to 12 in one short study, and the abuse, misuse, and addiction risks shared by stimulants. In adults, headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea were the most common adverse reactions. We also note what the regulator record does not contain: no announced pharmacy launch date, and no price or coverage information. Approval, scheduling, and actual availability are three different steps, and only the first two are complete in the sources above.

How it fits care here

ADHD is one of the conditions this practice treats, with medication management and, where it belongs in the plan, therapy for the skills and routines around the medicine. A new option changes a medication conversation only for a specific reason: a current medicine that has had a fair trial and is not controlling symptoms, side effects that limit daily life, or a schedule that does not fit the patient's day. For a patient whose treatment is working, this news changes nothing, and we say so plainly. Whether this particular medicine suits a particular patient is a visit decision, made against their cardiac history, blood pressure, other medicines including antidepressants, and any history of substance misuse, tics, or mania, which is the screening list the label itself sets out. We make no claim about the product beyond what the approval, the label, and the scheduling rule state.

Read more, by door

Each clinical site in this practice keeps its own blog, and each has written this topic for its own readers. For the medication focused read, PsychMed Care has published a new ADHD medicine, explained, covering the class, the trial numbers, and the safety warnings in detail. For the combined therapy and medication perspective, psych.us has published the new ADHD medicine in plain language, including what six weeks of evidence can and cannot hold, and where structure and skills work fit. When reading has done all it can, the booking page is the next step.

Sources

The summary above rests on the regulator sources below.

U.S. Food and Drug Administration prescribing information for Simtriyo (centanafadine), NDA 218145, revised October 2026: the approved indication, the boxed warnings, the warnings and precautions, the most common adverse reactions, and the four clinical studies in section 14. FDA prescribing information.

U.S. Food and Drug Administration approval letter for NDA 218145, July 24, 2026: the application is approved for the treatment of attention-deficit/hyperactivity disorder, and marketing was tied to completion of controlled substance scheduling. FDA approval letter.

Drug Enforcement Administration, Schedules of Controlled Substances: Placement of Centanafadine in Schedule III, interim final rule, Federal Register volume 91, page 68470, October 30, 2026, Docket No. DEA-1743: the rule is effective October 30, 2026, and comments are due November 30, 2026. DEA interim final rule in the Federal Register.

Please read this part

This post is educational and does not create a treatment relationship. The trials summarized here lasted six weeks and used placebo comparisons, so they cannot predict how any one person will respond or how this medicine compares with a treatment already working for them. Patients of this practice who want to discuss ADHD treatment options should raise the question at a visit, where their history, heart health, and full medication list can be weighed. This post gives no dosing information.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.